Skip to Content

Generic Aemcolo Availability

Last updated on July 7, 2021.

Aemcolo is a brand name of rifamycin, approved by the FDA in the following formulation(s):

AEMCOLO (rifamycin sodium - tablet, delayed release;oral)

  • Manufacturer: REDHILL
    Approval date: November 16, 2018
    Strength(s): EQ 194MG BASE [RLD]

Has a generic version of Aemcolo been approved?

No. There is currently no therapeutically equivalent version of Aemcolo available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Aemcolo. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Oral antimicrobial pharmaceutical compositions
    Patent 8,263,120
    Issued: September 11, 2012
    Inventor(s): Ajani; Mauro & Bozzella; Roberta & Celasco; Giuseppe & Villa; Roberto
    Assignee(s): Cosmo Technologies Ltd.

    The present invention relates to oral pharmaceutical compositions with controlled and/or programmed release containing at least one active ingredient having antimicrobial and/or anti-infectious activity for the treatment of infections of the large intestine, in particular the colon.

    Patent expiration dates:

    • May 3, 2025
      ✓ 
      Drug product
  • Oral antimicrobial pharmaceutical compositions
    Patent 8,486,446
    Issued: July 16, 2013
    Assignee(s): Cosmo Technologies Ltd.

    The present invention relates to oral pharmaceutical compositions with controlled and/or programmed release containing at least one active ingredient having antimicrobial and/or anti-infectious activity for the treatment of infections of the large intestine, in particular the colon.

    Patent expiration dates:

    • May 3, 2025
      ✓ 
      Drug product
  • Oral antimicrobial pharmaceutical compositions
    Patent 8,529,945
    Issued: September 10, 2013
    Assignee(s): Cosmo Technologies Ltd.

    The present invention relates to oral pharmaceutical compositions with controlled and/or programmed release containing at least one active ingredient having antimicrobial and/or anti-infectious activity for the treatment of infections of the large intestine, in particular the colon.

    Patent expiration dates:

    • May 3, 2025
      ✓ 
      Drug product
  • Oral antimicrobial pharmaceutical compositions
    Patent 8,741,948
    Issued: June 3, 2014
    Assignee(s): Cosmo Technologies Ltd.

    The present invention relates to oral pharmaceutical compositions with controlled and/or programmed release containing at least one active ingredient having antimicrobial and/or anti-infectious activity for the treatment of infections of the large intestine, in particular the colon.

    Patent expiration dates:

    • May 3, 2025
      ✓ 
      Patent use: TREATMENT OF TRAVELERS' DIARRHEA CAUSED BY NON-INVASIVE STRAINS OF ESCHERICHIA COLI IN ADULTS
      ✓ 
      Drug product

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.